Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
Tremonton
Archived
•
December 8, 2025
•
– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement –
Source: https://www.tremontonleader.com/search/?f=rss&t=article&l=50&c=news* - Read Original
"5000+ Emails weekly."
"We build AI or anything ICST"
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!
Sponsored
"Water and Showers while camping is so simple."
"Adventure is where you chose to go."